Rafferty Asset Management, LLC Cue Biopharma, Inc. Transaction History

Rafferty Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$4.41 - $12.28 $428,043 - $1.19 Million	-97,062 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$10.86 - $17.85 $630,466 - $1.04 Million	58,054 Added 148.83%	97,062 $1.1 Million
Q3 2021 Nov 10, 2021	SELL	$10.06 - $15.3 $136,252 - $207,223	-13,544 Reduced 25.77%	39,008 $568,000
Q2 2021 Aug 10, 2021	SELL	$10.9 - $14.53 $74,185 - $98,891	-6,806 Reduced 11.47%	52,552 $612,000
Q1 2021 May 10, 2021	BUY	$11.2 - $16.09 $517,462 - $743,390	46,202 Added 351.19%	59,358 $724,000
Q4 2020 Feb 10, 2021	SELL	$11.12 - $16.4 $225,246 - $332,198	-20,256 Reduced 60.62%	13,156 $165,000
Q3 2020 Nov 13, 2020	BUY	$15.05 - $23.54 $368,123 - $575,788	24,460 Added 273.24%	33,412 $503,000
Q2 2020 Aug 07, 2020	BUY	$12.7 - $30.73 $113,690 - $275,094	8,952 New	8,952 $219,000

14M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $45.3M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.